Standard treatments are designed to control the underlying mechanism of disease, but require time to take effect, time that aTTP patients do not have. Caplacizumab can shield patients from the formation of clots, giving standard therapies the time they need to kick-in. Caplacizumab saves lives and prevents disability.
